Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nighttime Mirabegron vs Antimuscarinics for Nocturia in Women
NCT07114640Phase 3Not yet recruiting
- Sponsor
- Far Eastern Memorial Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of mirabegron, solifenacin, tolterodine, oxybutynin in overactive bladder syndrome (OAB), nocturia, sponsored by Far Eastern Memorial Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
mirabegronsolifenacintolterodineoxybutynin
03
Conditions
overactive bladder syndrome (OAB)nocturia
Beyond the preview
Go deeper on NCT07114640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114640.